Franklin Resources
VRDN icon

Franklin Resources’s Viridian Therapeutics VRDN Stock Holding History

Franklin Resources’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-250,000
Closed -$2.89M – 2412
2022
Q2 		$2.89M Sell
250,000
-350,023
-58% -$4.7M ﹤0.01% 1253
2022
Q1 		$11.1M Hold
600,023
– – ﹤0.01% 986
2021
Q4 		$11.9M Buy
600,023
+23
+0% +$428 ﹤0.01% 1010
2021
Q3 		$9.87M Buy
+600,000
New +$8.8M ﹤0.01% 1060

Other funds holding VRDN

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Franklin Resources's VRDN Position: Q3 2022 in Review

Franklin Resources sold out of Viridian Therapeutics (VRDN) in Q3 2022, closing a stake of 250,000 shares — an estimated $2.89M sold.

Franklin Resources first reported a position in VRDN in Q3 2021 and held it in 4 quarters. The position peaked at $11.9M in Q4 2021. 105 funds tracked by Wall St. Rank hold VRDN as of Q3 2022.

  • Franklin Resources reported no remaining Viridian Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Franklin Resources sold 250,000 Viridian Therapeutics shares in Q3 2022, an estimated $2.89M.
  • Franklin Resources first reported a position in Viridian Therapeutics in Q3 2021 and held it in 4 quarters.
  • Franklin Resources's Viridian Therapeutics position peaked at $11.9M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2022.

Based on Franklin Resources's 13F filing for Q3 2022, filed 14 Nov 2022.